Table 4 Rates of Adverse Experiences (AEs) of Special Interest per 100 Patient-YearsAll Patients Over The Entire 52 Weeks From The Start of Therapy to the End of the Period
| Â | Â | Etoricoxib | Â | Diclofenac |
|---|---|---|---|---|
| Â | 30 mg | 60 mg | 90 mg | 150 mg |
|  | n (rate†) | n (rate†) | n (rate†) | n (rate†) |
Most Common Clinical AEs* | Â | Â | Â | Â |
   Diarrhea | 20 (15.4) | 9 (12.2) | 14 (13.4) | 14 (23.2) |
   Dizziness | 9 (6.9) | 8 (10.8) | 9 (8.6) | 1 (1.7) |
   Dyspepsia | 8 (6.1) | 3 (4.1) | 5 (4.8) | 8 (13.3) |
   Headache | 19 (14.6) | 18 (24.4) | 4 (3.8) | 4 (6.6) |
   Influenza-like disease | 18 (13.8) | 7 (9.5) | 6 (5.8) | 4 (6.6) |
   Lower Extremity Edema | 11 (8.4) | 9 (12.2) | 7 (6.7) | 2 (3.3) |
   Nausea | 14 (10.7) | 9 (12.2) | 10 (9.6) | 7 (11.6) |
   Rash | 6 (4.6) | 10 (13.5) | 4 (3.8) | 1 (1.7) |
   Sinusitis | 15 (11.5) | 5 (6.8) | 14 (13.4) | 5 (8.3) |
   Upper Respiratory Infection | 45 (34.5) | 31 (42.0) | 41 (39.3) | 26 (43.1) |
GI Nuissance Symptoms | Â | Â | Â | Â |
   Abdominal pain | 11 (8.4) | 4 (5.4) | 2 (1.9) | 5 (8.3) |
   Acid reflux | 0 (0) | 0 (0) | 0 (0) | 1 (1.7) |
   Dyspepsia | 8 (6.1) | 3 (4.1) | 5 (4.8) | 8 (13.3) |
   Epigastric discomfort | 4 (3.1) | 1 (1.4) | 6 (5.8) | 2 (3.3) |
   Heartburn | 7 (5.4) | 7 (9.5) | 9 (8.6) | 6 (9.9) |
   Nausea | 14 (10.7) | 9 (12.2) | 10 (9.6) | 7 (11.6) |
   Vomiting | 3 (2.3) | 1 (1.4) | 0 (0) | 1 (1.7) |
Renovascular AEs | Â | Â | Â | Â |
   Lower extremity edema | 11 (8.4) | 9 (12.2) | 7 (6.7) | 2 (3.3) |
   Congestive heart failure | 0 (0) | 2 (2.7) | 0 (0) | 0 (0) |
   Hypertension | 7 (5.4) | 4 (5.4) | 10 (9.6) | 5 (8.3) |